MX342782B - Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos. - Google Patents
Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.Info
- Publication number
- MX342782B MX342782B MX2013001716A MX2013001716A MX342782B MX 342782 B MX342782 B MX 342782B MX 2013001716 A MX2013001716 A MX 2013001716A MX 2013001716 A MX2013001716 A MX 2013001716A MX 342782 B MX342782 B MX 342782B
- Authority
- MX
- Mexico
- Prior art keywords
- amyloid beta
- beta peptide
- peptide antibodies
- n3pglu
- n3pglu amyloid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un anticuerpos Aß anti-N3pGlu o su fragmento de unión a antígeno del mismo diseñado por ingeniería, que comprende una región variable de cadena ligera (LCVR) y una región variable de cadena pesada (HCVR), caracterizado porque tal LCVR comprende los polipépitdos LCDR1, LCDR2, y LCDR3, y la HCVR comprende los polipéptidos LCDR1, LCDR2, y LCDR3, los cuales se seleccionan a partir de a) SEQ ID NO: 3, SEQ ID NO: 4 LDCR3 es SEQ ID NO: 5, HCDR1 es SEQ ID NO: 6, HCDR2 es SEQ ID NO: 8, y HCDR3 SEQ ID NO: 9 b) LCDR1 es SEQ ID NO: 3, LCDR2 SEQ ID NO: 4 LCDR3 es SEQ IDNO:5 HCDR1 SEQ ID NO: 7 HCDR2 es SEQ ID NO: 8 y HCDR3 es SEQ ID NO:10 c) LCDR1 es SEQ ID NO:3, LCDR2 es SEQ ID NO:4 LCDR3 SEQ ID NO: 5 HCDR1 SEQ ID NO: 40 HCDR2 SEQ ID NO:8, y HCDR3 SEQ ID NO: 41 d) LDR1 SEQ ID NO:3 LCDR2 SEQ ID NO: 35, LCDR3 SEQ ID NO:5, HCDR1 SEQ ID NO: 7, HCDR2 SEQ ID NO: 8 y HCDR3 SEQ ID NO:10, y e) LCDR1 SEQ ID NO: 45 LCDR2 SEQ ID NO: 4, LCDR3 es SEQ ID NO:5, HCDR1 SEQ ID NO:40, HCDR2 SEQ ID NO: 8 y HCDR3 SEQ ID NO: 46.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37302610P | 2010-08-12 | 2010-08-12 | |
| PCT/US2011/046994 WO2012021469A1 (en) | 2010-08-12 | 2011-08-09 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013001716A MX2013001716A (es) | 2013-10-28 |
| MX342782B true MX342782B (es) | 2016-10-12 |
Family
ID=44543826
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013001716A MX342782B (es) | 2010-08-12 | 2011-08-09 | Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos. |
| MX2016005533A MX355268B (es) | 2010-08-12 | 2013-02-12 | Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005533A MX355268B (es) | 2010-08-12 | 2013-02-12 | Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos. |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8679498B2 (es) |
| EP (3) | EP3042917B1 (es) |
| JP (2) | JP5980207B2 (es) |
| KR (1) | KR101498833B1 (es) |
| CN (2) | CN103068848B (es) |
| AU (1) | AU2011289629B2 (es) |
| BR (1) | BR112013004056B8 (es) |
| CA (1) | CA2805114C (es) |
| CL (1) | CL2013000390A1 (es) |
| CO (1) | CO6670526A2 (es) |
| CR (1) | CR20130016A (es) |
| CY (2) | CY1120144T1 (es) |
| DK (3) | DK3339323T3 (es) |
| DO (1) | DOP2013000029A (es) |
| EA (1) | EA023021B1 (es) |
| EC (1) | ECSP13012436A (es) |
| ES (3) | ES2764728T3 (es) |
| GT (1) | GT201300036A (es) |
| HK (1) | HK1180703A1 (es) |
| HR (3) | HRP20160151T1 (es) |
| HU (2) | HUE037524T2 (es) |
| IL (2) | IL224030B (es) |
| LT (2) | LT3042917T (es) |
| MA (1) | MA34461B1 (es) |
| ME (3) | ME02352B (es) |
| MX (2) | MX342782B (es) |
| MY (2) | MY163521A (es) |
| NO (1) | NO3042917T3 (es) |
| NZ (2) | NZ626665A (es) |
| PE (1) | PE20130817A1 (es) |
| PH (1) | PH12013500277A1 (es) |
| PL (3) | PL2603523T3 (es) |
| PT (2) | PT3339323T (es) |
| RS (3) | RS54685B1 (es) |
| SG (2) | SG10201509330XA (es) |
| SI (3) | SI3339323T1 (es) |
| UA (1) | UA107600C2 (es) |
| WO (1) | WO2012021469A1 (es) |
| ZA (1) | ZA201300437B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| ME02352B (me) * | 2010-08-12 | 2016-06-20 | Lilly Co Eli | PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| WO2015113169A1 (en) * | 2014-02-03 | 2015-08-06 | Cnj Holdings, Inc. | Humanized beta-amyloid binding molecules and uses thereof |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| ES2779977T3 (es) | 2014-07-10 | 2020-08-21 | Univ Zuerich | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| EP3234611A1 (en) | 2014-12-19 | 2017-10-25 | Probiodrug AG | Novel method for the detection of pglu-abeta peptides |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| LT3353212T (lt) * | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| US10889643B2 (en) | 2016-01-11 | 2021-01-12 | Universität Zürich | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TW201740944A (zh) * | 2016-03-15 | 2017-12-01 | 美國禮來大藥廠 | 組合療法 |
| AR107774A1 (es) * | 2016-03-16 | 2018-05-30 | Lilly Co Eli | Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| WO2018031361A2 (en) * | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
| CN109641052A (zh) * | 2016-08-18 | 2019-04-16 | 伊莱利利公司 | BACE-1抑制剂和抗-N3pGlu Aβ抗体的组合疗法 |
| AR110470A1 (es) | 2016-10-21 | 2019-04-03 | Lilly Co Eli | Terapia de combinación para tratar la enfermedad de alzheimer |
| US10912773B2 (en) | 2016-10-28 | 2021-02-09 | H. Lundbeck A/S | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors |
| US10905688B2 (en) | 2016-10-28 | 2021-02-02 | H. Lundbeck A/S | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors |
| TW201827467A (zh) * | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| FI3672631T3 (fi) | 2017-08-22 | 2023-06-29 | Biogen Ma Inc | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| US11634416B2 (en) | 2017-12-14 | 2023-04-25 | H. Lundbeck A/S | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines |
| CN111511742B (zh) | 2017-12-20 | 2023-10-27 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| CN113891746A (zh) | 2019-03-26 | 2022-01-04 | 詹森药业有限公司 | 焦谷氨酸淀粉样蛋白-β的抗体及其用途 |
| JP7551744B2 (ja) | 2019-10-15 | 2024-09-17 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株 |
| WO2021257808A2 (en) * | 2020-06-17 | 2021-12-23 | Proviva Therapeutics (Hong Kong) Limited | Antibodies to fibroblast activation protein and b7h3 |
| TW202216760A (zh) | 2020-07-23 | 2022-05-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 抗類澱粉β (ABETA)抗體 |
| CN116547292A (zh) | 2020-10-02 | 2023-08-04 | 伊莱利利公司 | 用于减少抗体纯化过程中的宿主细胞蛋白质含量的方法和具有减少的宿主细胞蛋白质含量的抗体组合物 |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2023070064A1 (en) | 2021-10-22 | 2023-04-27 | Eli Lilly And Company | O-glcnacase (oga) inhibitor combination therapy |
| CN118510800A (zh) | 2021-10-29 | 2024-08-16 | 伊莱利利公司 | 靶向白细胞介素-34的化合物和方法 |
| CA3236555A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| WO2023076970A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| KR20240099347A (ko) | 2021-10-29 | 2024-06-28 | 일라이 릴리 앤드 캄파니 | 인터류킨-34를 표적화하는 화합물 및 방법 |
| IL314657A (en) | 2022-02-03 | 2024-09-01 | Lilly Co Eli | Regional tau imaging for diagnosing and treating alzheimer's disease |
| IL318102A (en) * | 2022-07-21 | 2025-02-01 | Lilly Co Eli | Pharmaceutical solutions of anti-n3pglu aβ antibodies and their uses |
| WO2024133925A1 (en) | 2022-12-22 | 2024-06-27 | Bioarctic Ab | Antibody which binds to abetape3 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| WO2004013172A2 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| WO2005018424A2 (en) * | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| KR100889430B1 (ko) * | 2004-02-23 | 2009-03-23 | 일라이 릴리 앤드 캄파니 | 항-Ａβ 항체 |
| EP1781704A2 (en) * | 2004-07-30 | 2007-05-09 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| MX2009000476A (es) | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Anticuerpo humanizado contra beta amiloide. |
| US20080292625A1 (en) * | 2007-04-18 | 2008-11-27 | Sally Schroeter | Prevention and treatment of cerebral amyloid angiopathy |
| CA2723995A1 (en) | 2008-06-12 | 2009-12-17 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| EP2321348A2 (en) | 2008-07-09 | 2011-05-18 | University of Zürich | Method of promoting neurogenesis |
| KR101706789B1 (ko) * | 2008-07-21 | 2017-02-14 | 프로비오드룩 아게 | 진단용 항체 검사법 |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| ME02352B (me) * | 2010-08-12 | 2016-06-20 | Lilly Co Eli | PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA |
-
2011
- 2011-08-09 ME MEP-2016-28A patent/ME02352B/me unknown
- 2011-08-09 SI SI201131817T patent/SI3339323T1/sl unknown
- 2011-08-09 ES ES18150424T patent/ES2764728T3/es active Active
- 2011-08-09 PL PL11745672T patent/PL2603523T3/pl unknown
- 2011-08-09 SG SG10201509330XA patent/SG10201509330XA/en unknown
- 2011-08-09 AU AU2011289629A patent/AU2011289629B2/en active Active
- 2011-08-09 US US13/810,895 patent/US8679498B2/en active Active
- 2011-08-09 PL PL15196358T patent/PL3042917T3/pl unknown
- 2011-08-09 LT LTEP15196358.4T patent/LT3042917T/lt unknown
- 2011-08-09 JP JP2013524156A patent/JP5980207B2/ja active Active
- 2011-08-09 ME MEP-2018-79A patent/ME03032B/me unknown
- 2011-08-09 SI SI201131449T patent/SI3042917T1/en unknown
- 2011-08-09 DK DK18150424.2T patent/DK3339323T3/da active
- 2011-08-09 HU HUE15196358A patent/HUE037524T2/hu unknown
- 2011-08-09 CN CN201180039876.1A patent/CN103068848B/zh active Active
- 2011-08-09 DK DK11745672.3T patent/DK2603523T3/en active
- 2011-08-09 CA CA2805114A patent/CA2805114C/en active Active
- 2011-08-09 CN CN201510613319.6A patent/CN105111308B/zh active Active
- 2011-08-09 RS RS20160129A patent/RS54685B1/en unknown
- 2011-08-09 SG SG2013005210A patent/SG187586A1/en unknown
- 2011-08-09 ES ES11745672.3T patent/ES2564252T3/es active Active
- 2011-08-09 DK DK15196358.4T patent/DK3042917T3/en active
- 2011-08-09 PL PL18150424T patent/PL3339323T3/pl unknown
- 2011-08-09 NO NO15196358A patent/NO3042917T3/no unknown
- 2011-08-09 ES ES15196358.4T patent/ES2664128T3/es active Active
- 2011-08-09 HU HUE11745672A patent/HUE028678T2/en unknown
- 2011-08-09 EP EP15196358.4A patent/EP3042917B1/en active Active
- 2011-08-09 BR BR112013004056A patent/BR112013004056B8/pt active IP Right Grant
- 2011-08-09 RS RS20180323A patent/RS57026B1/sr unknown
- 2011-08-09 SI SI201130740T patent/SI2603523T1/sl unknown
- 2011-08-09 WO PCT/US2011/046994 patent/WO2012021469A1/en active Application Filing
- 2011-08-09 EA EA201270813A patent/EA023021B1/ru not_active IP Right Cessation
- 2011-08-09 MX MX2013001716A patent/MX342782B/es active IP Right Grant
- 2011-08-09 RS RS20191581A patent/RS59652B1/sr unknown
- 2011-08-09 NZ NZ626665A patent/NZ626665A/en unknown
- 2011-08-09 EP EP18150424.2A patent/EP3339323B1/en active Active
- 2011-08-09 LT LTEP18150424.2T patent/LT3339323T/lt unknown
- 2011-08-09 ME MEP-2019-356A patent/ME03661B/me unknown
- 2011-08-09 MY MYPI2013700226A patent/MY163521A/en unknown
- 2011-08-09 MA MA35653A patent/MA34461B1/fr unknown
- 2011-08-09 NZ NZ606095A patent/NZ606095A/en unknown
- 2011-08-09 PH PH1/2013/500277A patent/PH12013500277A1/en unknown
- 2011-08-09 MY MYPI2016001651A patent/MY181969A/en unknown
- 2011-08-09 EP EP11745672.3A patent/EP2603523B1/en active Active
- 2011-08-09 KR KR1020137003412A patent/KR101498833B1/ko active IP Right Grant
- 2011-08-09 PT PT181504242T patent/PT3339323T/pt unknown
- 2011-08-09 PE PE2013000253A patent/PE20130817A1/es active IP Right Grant
- 2011-08-09 PT PT151963584T patent/PT3042917T/pt unknown
- 2011-09-08 UA UAA201301508A patent/UA107600C2/ru unknown
-
2012
- 2012-12-31 IL IL224030A patent/IL224030B/en unknown
-
2013
- 2013-01-16 ZA ZA2013/00437A patent/ZA201300437B/en unknown
- 2013-01-16 CR CR20130016A patent/CR20130016A/es unknown
- 2013-02-05 DO DO2013000029A patent/DOP2013000029A/es unknown
- 2013-02-08 EC ECSP13012436 patent/ECSP13012436A/es unknown
- 2013-02-08 CL CL2013000390A patent/CL2013000390A1/es unknown
- 2013-02-08 GT GT201300036A patent/GT201300036A/es unknown
- 2013-02-12 MX MX2016005533A patent/MX355268B/es unknown
- 2013-02-12 CO CO13028596A patent/CO6670526A2/es unknown
- 2013-07-11 HK HK13108135.4A patent/HK1180703A1/zh unknown
- 2013-09-27 US US14/039,113 patent/US8961972B2/en active Active
-
2016
- 2016-02-10 HR HRP20160151TT patent/HRP20160151T1/hr unknown
- 2016-04-22 JP JP2016086317A patent/JP6395755B2/ja active Active
-
2018
- 2018-04-18 HR HRP20180616TT patent/HRP20180616T1/hr unknown
- 2018-04-20 CY CY20181100420T patent/CY1120144T1/el unknown
-
2019
- 2019-12-12 HR HRP20192233TT patent/HRP20192233T1/hr unknown
-
2020
- 2020-01-07 CY CY20201100005T patent/CY1122458T1/el unknown
-
2021
- 2021-07-29 IL IL285226A patent/IL285226B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX355268B (es) | Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos. | |
| EP2579894A4 (en) | Cgrp antibodies | |
| MX2019012445A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| WO2014124334A3 (en) | Transthyretin antibodies and uses thereof | |
| NZ730763A (en) | Methods of treating a tauopathy | |
| MX2018005720A (es) | Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello. | |
| NZ727020A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| MY159398A (en) | Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| EP3702372A3 (en) | Anti-cd40 human antibodies | |
| SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
| EP2614085A4 (en) | ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE | |
| MX355543B (es) | Macrociclos peptidomiméticos. | |
| NZ718280A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
| PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
| IN2014DN05885A (es) | ||
| NZ626242A (en) | Anti-asic1 antibodies and uses thereof | |
| MX2015004763A (es) | Anticuerpos contra el beta-amiloide. | |
| PH12015501360A1 (en) | Bmp-6 antibodies | |
| MX2015002465A (es) | Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1). | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions | |
| WO2016007919A3 (en) | Antibody fragments for detecting cancer and methods of use | |
| HK1243439A1 (zh) | Pcsk9抗體、其抗原結合片段及其醫藥用途 | |
| TN2013000045A1 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |